Project Grant R01CA311683
Award Date 7/13/26
Completion Date 6/30/31
Dollars Obligated $518K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Jackson, MS 39216, USA
Similar Awards
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded University of California, Davis a $551,328 Project Grant under the Cancer Treatment Research program (CFDA 93.395) effective April 1, 2026, with completion targeted for March 31, 2031. This research initiative, "Dissecting the Role of CPT1C in Advanced Prostate Cancer," focuses on elucidating the molecular mechanisms and therapeutic potential of carnitine palmitoyltransferase 1C (CPT1C) in neuroendocrine...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $410,933 Project Grant to the University of California, San Diego under the Cancer Treatment Research program (CFDA 93.395) on March 18, 2026, with completion anticipated by February 29, 2028. This exploratory research initiative (R21) focuses on developing next-generation small interfering RNA (siRNA) therapeutics to treat metastatic castration-resistant prostate cancer (mCRPC). The primary deliverable is the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded The Johns Hopkins University a Project Grant totaling $658,423 under the Cancer Biology Research program (CFDA 93.396) effective July 1, 2026 through June 30, 2031. This award supports fundamental research on therapeutic targeting of PI3K gamma (PI3Kγ)-positive tumor-associated macrophages (TAMs) in metastatic castration-resistant prostate cancer (MCRPC) to reduce health disparities. The research builds on the investigator...
- Federal Grant Award Summary Oregon Health & Science University received a $1,042,004 Project Grant from the National Cancer Institute (NCI) under the Cancer Biology Research program (CFDA 93.396), awarded on March 26, 2026, with a completion date of February 28, 2031. The award funds development and validation of a microphysiological bone metastasis-on-a-chip platform designed to advance understanding of prostate cancer metastasis to bone, which occurs in over 80% of advanced prostate cancer...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded Fred Hutchinson Cancer Center a $723,547 Project Grant under the Cancer Biology Research program (CFDA 93.396) on June 9, 2026, for a five-year research initiative extending through May 31, 2031. The grant funds fundamental research to delineate the role of 5' untranslated regions (5' UTRs) in prostate cancer clonality—specifically, how these regulatory RNA elements modulate protein synthesis and influence clonal...
- Federal Project Grant Award Summary The National Cancer Institute awarded $498,775 to The Research Foundation for the State University of New York (operating as Stony Brook University) under the Cancer Biology Research program (CFDA 93.396) for a five-year project beginning July 1, 2026, and concluding June 30, 2031. The project, titled "Investigating Targetable Mechanisms of Altered Cell States in Castration-Resistant Prostate Cancer," will deliver fundamental cancer biology...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded a $588,677 Project Grant under the Cancer Biology Research program (CFDA 93.396) to the University of Arizona, with an award date of July 1, 2026, and a project completion date of June 30, 2031. The research focuses on identifying the mechanisms by which oxygen-dependent centrosome instability drives prostate cancer progression. Specifically, the project investigates how hypoxia induces centrosome loss and...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $714,317 under the Cancer Biology Research program (CFDA 93.396) to support fundamental research on prostate cancer progression and therapeutic resistance. The five-year award, effective August 1, 2025 through July 31, 2030, funds research investigating the molecular mechanisms linking epithelial-mesenchymal transition (EMT), mesenchymal-epithelial transition...
- Federal Project Grant Award Summary The National Cancer Institute (NCI) awarded $606,219 to the University of Miami's Office of Research Administration–School of Medicine on July 2, 2026, under the Cancer Biology Research program (CFDA 93.396) to support a five-year project through June 30, 2031. The project investigates signal transduction, cell biology, and molecular pharmacology of OR51E1, an olfactory G protein-coupled receptor (GPCR) ectopically expressed in prostate cancer and other...
- Federal Project Grant Award Summary The National Cancer Institute (NCI), under the Cancer Research Manpower program (CFDA 93.398), awarded the University of Wisconsin - Madison a $113,766 Project Grant on January 12, 2026, with a completion date of July 16, 2028. This award supports a research initiative combining antigen-specific vaccination with radiopharmaceutical therapy (RPT) to enhance anti-tumor immunity against metastatic castration-resistant prostate cancer. The project delivers...